Mahnaz Momenzadeh
1* 
, Maryam Khosravian
2 , Bhaskar VKS Lakkakula
3 1 Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
2 Institute of Biology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
3 Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur, India
Abstract
Metabolic bone disorder is an abnormality of bones indicated by reduced bone mass and high risk of fractures. Several lines of evidence have demonstrated that the local bone tissue renin-angiotensin system (RAS) is directly involved in bone metabolism and influences the bone health. This review aimed to assess the role of RAS in bone metabolism and comparative effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in reducing the bone fractures. In summary, the clinical trials, in vivo studies, and functional - pharmacological experiments suggested that the RAS regulates bone marrow metabolism and influences the bone health. Hence, it warrants further investigation on the role of ACEIs and ARBs in reducing risk fractures.
Implication for health policy/practice/research/medical education:
Several studies have demonstrated that the local bone tissue renin-angiotensin system (RAS) is directly involved in bone metabolism and influences the bone health.
Please cite this paper as: Momenzadeh M, Khosravian M, Lakkakula BVKS. Potential of renin-angiotensin system inhibition to improve metabolic bone disorders. J Nephropharmacol. 2021;10(2):e16. DOI: 10.34172/npj.2021.16.